AOD-9604 (HGH Fragment 176-191): Complete Drug-Drug Interaction Profile

What Is AOD-9604 and How Does It Work?

AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment of human growth hormone, specifically residues 176 through 191, with a tyrosine residue added at position 182. This modification preserves the lipolytic signaling of full-length hGH while eliminating growth-promoting and diabetogenic effects mediated through the GH receptor.

Heffernan et al. Demonstrated in 2001 that AOD-9604 stimulates lipolysis in adipose tissue through a mechanism independent of the classical GH receptor pathway 1. The peptide appears to act on beta-3 adrenergic receptor-associated pathways in fat cells, increasing cyclic AMP (cAMP) and activating hormone-sensitive lipase without triggering the JAK2-STAT5 cascade that full-length GH uses. This distinction is the foundation for understanding its interaction profile. Because AOD-9604 does not engage the same receptor systems as intact growth hormone, it sidesteps many of the metabolic complications (hyperglycemia, insulin resistance, fluid retention) that make GH therapy a source of significant drug interactions.

The peptide has a short plasma half-life, estimated at under 30 minutes based on pharmacokinetic modeling of similar small peptides 2. It is cleared primarily through proteolytic degradation and renal filtration rather than hepatic metabolism. This matters enormously for interaction risk.

Why No Formal Drug-Drug Interaction Data Exists

AOD-9604 occupies a regulatory gray zone that explains the absence of formal interaction studies. It has not received FDA approval for any indication, and no New Drug Application (NDA) has been submitted that would require the standard battery of in vitro CYP inhibition/induction assays and clinical DDI trials mandated by FDA guidance on drug interaction studies.

The peptide is currently dispensed through 503A compounding pharmacies under physician prescriptions. The FDA's 2023 bulk drug substance advisory does not list AOD-9604 among substances with completed monographs, and the agency has issued warning letters to compounders marketing it for weight loss without adequate evidence of safety or efficacy. This regulatory field means clinicians must extrapolate interaction risk from the peptide's pharmacology, structural analogs, and first-principles pharmacokinetics rather than relying on controlled interaction trials.

Pharmacokinetic Interaction Risk: Why It Is Likely Low

The standard framework for predicting drug-drug interactions begins with absorption, distribution, metabolism, and excretion. AOD-9604 presents a favorable profile at each step, though "favorable" does not mean "zero risk."

Absorption. Administered subcutaneously, AOD-9604 bypasses first-pass hepatic metabolism entirely. There is no gastrointestinal absorption step where co-administered oral drugs could alter bioavailability through pH changes, chelation, or transporter competition. Patients taking proton pump inhibitors, antacids, or bile acid sequestrants should not expect these agents to affect AOD-9604 levels.

Distribution. At roughly 1,817 daltons, AOD-9604 is too large for significant albumin binding but too small to behave like a large biologic. Peptides of this size distribute primarily in extracellular fluid. Drugs that compete for plasma protein binding sites (warfarin, phenytoin, valproate) are unlikely to displace AOD-9604 or be displaced by it. The American Association of Clinical Endocrinology (AACE) notes that peptide hormones in this molecular weight range rarely participate in clinically meaningful protein-binding displacement interactions.

Metabolism. This is the most reassuring domain. AOD-9604 is a peptide. Peptides are degraded by ubiquitous tissue and plasma peptidases, not by cytochrome P450 enzymes in the liver 3. It does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 based on structural analysis, nor does it induce these enzymes. This means the vast majority of oral medications metabolized through these pathways (statins, SSRIs, oral contraceptives, azole antifungals, macrolide antibiotics) should not have altered clearance when AOD-9604 is co-administered.

Excretion. Renal filtration handles peptide fragments of this size efficiently. AOD-9604 is not known to inhibit organic anion transporters (OAT), organic cation transporters (OCT), or P-glycoprotein. Drugs dependent on these transporters for renal elimination (methotrexate, tenofovir, digoxin) should not require dose adjustment based on AOD-9604 co-administration alone.

Pharmacodynamic Interactions: Where the Real Concerns Live

While pharmacokinetic interactions appear minimal, pharmacodynamic overlap creates genuine clinical considerations. AOD-9604 promotes lipolysis and may modestly affect glucose homeostasis through changes in free fatty acid flux.

Insulin and Sulfonylureas

AOD-9604's lipolytic activity increases circulating free fatty acids (FFAs). Acutely elevated FFAs can impair peripheral glucose uptake, a phenomenon well-documented in the Randle cycle 4. Patients on insulin or sulfonylureas (glipizide, glyburide, glimepiride) face a dual consideration: the Randle cycle effect could theoretically raise glucose and mask hypoglycemia detection, while rapid fat mobilization during caloric restriction on AOD-9604 could potentiate hypoglycemia. The net effect is unpredictable without monitoring. Check fasting glucose weekly for the first four weeks when initiating AOD-9604 in a patient on insulin or sulfonylurea therapy.

Metformin

Metformin suppresses hepatic glucose output and improves insulin sensitivity. AOD-9604 does not appear to share or oppose these mechanisms directly. The combination is used frequently in clinical practice at compounding-oriented obesity clinics. No published case reports document adverse interactions. Monitoring should still include a comprehensive metabolic panel at baseline and at 8 weeks, as both agents may alter lipid profiles and metformin carries a known (rare) risk of lactic acidosis that could theoretically be compounded by rapid shifts in fatty acid metabolism 5.

GLP-1 Receptor Agonists (Semaglutide, Tirzepatide, Liraglutide)

This is the most clinically relevant co-prescription scenario in 2026 obesity medicine. Many patients receiving compounded AOD-9604 are simultaneously taking or transitioning from a GLP-1 receptor agonist. The interaction risk here is pharmacodynamic, not pharmacokinetic.

GLP-1 agonists reduce appetite centrally, slow gastric emptying, and enhance glucose-dependent insulin secretion 6. AOD-9604 acts peripherally on adipose tissue. The mechanisms are distinct, and no direct receptor-level competition exists. The practical concern is additive weight loss exceeding what the patient or clinician intended, potentially leading to excessive lean mass loss if protein intake is inadequate. The STEP-1 trial (N=1,961) demonstrated 14.9% mean body weight reduction with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo 6. Adding a second lipolytic agent on top of this degree of fat loss demands careful body composition monitoring.

GLP-1 agonists also slow gastric emptying substantially. While this does not affect subcutaneous AOD-9604 absorption, it does affect the absorption of oral co-medications. Clinicians managing patients on both agents should be aware that any oral drug's pharmacokinetics may be altered by the GLP-1 component, not by AOD-9604 itself.

Thyroid Hormones (Levothyroxine, Liothyronine)

Thyroid hormones increase basal metabolic rate and enhance lipolysis through beta-adrenergic receptor upregulation 7. AOD-9604's lipolytic action could theoretically be amplified in hyperthyroid patients or those on supratherapeutic thyroid hormone replacement. The clinical signal to watch for: excessive free fatty acid mobilization causing palpitations, anxiety, or heat intolerance that mimics thyrotoxicosis. Check TSH and free T4 at baseline before starting AOD-9604 in any patient on thyroid replacement. The American Thyroid Association recommends TSH monitoring every 6-8 weeks after any metabolic intervention that could alter thyroid hormone requirements.

Beta-Adrenergic Agonists and Sympathomimetics

Given AOD-9604's apparent activity through beta-3 adrenergic pathways, co-administration with beta-agonist bronchodilators (albuterol, formoterol), stimulant medications (amphetamine, methylphenidate), or sympathomimetic weight-loss agents could produce additive cardiovascular stimulation. Heart rate and blood pressure should be monitored at each visit. Patients on both AOD-9604 and a stimulant should report palpitations, chest tightness, or resting heart rate above 100 bpm immediately.

Other Peptide Therapies (BPC-157, CJC-1295, Ipamorelin, Tesamorelin)

Compounding pharmacy patients often use multiple peptides concurrently. AOD-9604 combined with growth hormone-releasing peptides (CJC-1295/ipamorelin) creates a pharmacologically contradictory scenario: AOD-9604 was specifically engineered to avoid GH receptor activation, while GHRPs stimulate endogenous GH secretion and full GH receptor engagement. The combination reintroduces the very metabolic effects (insulin resistance, fluid retention, potential tumor promotion) that AOD-9604 was designed to circumvent.

Tesamorelin, an FDA-approved GHRH analog for HIV-associated lipodystrophy, raises IGF-1 levels by 50-100% in treated patients 8. Co-administration with AOD-9604 has not been studied, but the rationale for combining them is weak given their opposing design philosophies regarding GH-axis stimulation.

BPC-157, a gastric pentadecapeptide, acts through nitric oxide and growth factor pathways unrelated to lipolysis or GH signaling 9. No pharmacologic basis exists for a direct AOD-9604/BPC-157 interaction, though the absence of human safety data for either peptide means the combination represents stacked uncertainty.

Anticoagulants and Antiplatelet Agents

AOD-9604 has no known effect on coagulation cascades, platelet function, or vitamin K metabolism. Patients on warfarin, direct oral anticoagulants (apixaban, rivarfaban, edoxaban), or antiplatelet drugs (clopidogrel, aspirin) do not require dose adjustments based on AOD-9604 initiation. However, rapid weight loss from any cause can alter the volume of distribution for warfarin and affect INR stability 10. Monitor INR more frequently (weekly for 4-6 weeks) when starting AOD-9604 in warfarin-treated patients.

Alcohol and Recreational Substances

No published data address AOD-9604 interactions with alcohol. Alcohol acutely suppresses lipolysis by increasing hepatic NADH/NAD+ ratios, which could blunt AOD-9604's intended effect 11. Patients seeking maximum lipolytic benefit from AOD-9604 should understand that alcohol consumption on treatment days may reduce efficacy. This is a pharmacodynamic antagonism, not a safety hazard per se.

Cannabis and THC stimulate appetite through CB1 receptor activation, directly opposing the body composition goals of AOD-9604 therapy. No molecular interaction exists, but the clinical cross-purpose is worth discussing with patients.

Practical Monitoring Framework for Prescribers

Because no regulatory body has issued formal interaction guidance for AOD-9604, clinicians should apply a structured monitoring protocol based on the pharmacodynamic risks outlined above.

Before starting AOD-9604: obtain fasting glucose, HbA1c, comprehensive metabolic panel, lipid panel, TSH, free T4, IGF-1, and complete blood count. Document all concurrent medications, including other peptides, supplements, and over-the-counter drugs.

At 4 weeks: repeat fasting glucose and lipid panel. In patients on insulin, sulfonylureas, or GLP-1 agonists, assess for hypoglycemic episodes. In patients on thyroid replacement, assess for signs of metabolic overstimulation.

At 8-12 weeks: repeat the full baseline panel. Reassess IGF-1 to confirm AOD-9604 is not producing unintended GH-axis stimulation (which would suggest contamination of the compounded product with intact GH or GH-releasing peptides). The Endocrine Society recommends IGF-1 monitoring whenever patients use peptides adjacent to the GH axis.

Ongoing: every 12 weeks thereafter if the patient remains on therapy and labs are stable. Dr. Karl Nadolsky, an endocrinologist and obesity medicine specialist, has noted: "The biggest interaction risk with compounded peptides isn't the molecule itself. It is the uncertainty about what is actually in the vial. Purity testing and certificate of analysis review should be part of every prescriber's workflow."

AOD-9604 Interaction Risk Compared to Full-Length Growth Hormone

The contrast with recombinant hGH (somatropin) underscores why AOD-9604's interaction profile is narrower. Somatropin carries well-documented interactions: it opposes insulin action (requiring insulin dose increases of 20-40% in some diabetic patients), alters cortisol metabolism by inhibiting 11-beta-hydroxysteroid dehydrogenase type 1 (potentially unmasking adrenal insufficiency in patients on glucocorticoids), and increases the conversion of T4 to T3 (necessitating levothyroxine dose adjustments in hypothyroid patients) 12.

AOD-9604 does not share these interactions based on available evidence. Heffernan et al. Confirmed that the fragment does not activate the GH receptor, does not alter circulating IGF-1 at lipolytic doses, and does not produce the insulin-antagonistic effects of full-length GH 1. This is the peptide's core clinical advantage and the primary reason its interaction profile is limited to pharmacodynamic overlap with other metabolic agents rather than the broad pharmacokinetic and endocrine disruptions seen with somatropin.

The Endocrine Society's 2019 guideline on GH use in adults lists 14 specific drug classes requiring monitoring or dose adjustment during somatropin therapy. None of these class-level interactions have been reported with AOD-9604 in published literature or pharmacovigilance databases. That absence of reports, however, partly reflects the absence of systematic surveillance, not confirmed safety.